Home / Leaderboard / Cowen Inc.
Cowen Inc.
Jeffrey Solomon · Asset Manager · Multi-Strategy
Cowen Inc., now operating as TD Cowen following its acquisition by TD Bank Group in March 2023, is a multifaceted financial services institution founded in 1918. Headquartered in New York, the firm has established a formidable reputation in investment banking, equity and credit research, sales and trading, and prime brokerage. Through its investment management arm, Cowen Investment Management, the institution offers a range of alternative investment strategies, including healthcare royalties, activism, and growth equity. Cowen is particularly distinguished by its proprietary research capabilities and its history of identifying high-growth sectors, such as biotechnology and cannabis, ahead of the broader market. As a division of TD Securities, it continues to serve global institutional and corporate clients with a focus on delivering value through specialized industry expertise and innovative financial solutions.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +20.0% |
| YTD return | +1.6% |
| Sharpe ratio | 3.24 |
| Win rate | 69% |
| AUM | $0.8B |
| Inception | Oct 1, 2025 |
| Updated | Sep 21, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $0.8B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://www.cowen.com |
Current Holdings
Updated on Sep 21, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| PTCT | PTC Therapeutics Inc | 24.5% | +2.0% |
| NVDA | NVIDIA Corporation | 24.3% | +21.6% |
| STOK | Stoke Therapeutics Inc | 12.4% | +11.6% |
| TSLA | Tesla Inc | 7.6% | -14.5% |
| IMTX | Immatics NV | 6.6% | -6.4% |
| PTGX | Protagonist Therapeutics Inc | 5.1% | +107.8% |
| TARS | Tarsus Pharmaceuticals Inc | 4.6% | +30.4% |
| ESTA | Establishment Labs Holdings Inc | 4.5% | +40.0% |
| ET | Energy Transfer LP | 2.3% | +20.0% |
| NGNE | Neurogene Inc | 2.1% | +75.9% |
| TSHA | Taysha Gene Therapies Inc | 1.4% | +39.6% |
| CMPS | Compass Pathways Plc | 1.1% | +143.4% |
| EURK | Eureka Acquisition Corp Class A Ordinary Share | 0.6% | +5.6% |
| GBX | Greenbrier Companies Inc | 0.6% | -13.7% |
| POLE | Andretti Acquisition Corp. II Class A Ordinary Shares | 0.5% | +2.0% |
| ORKA | Oruka Therapeutics, Inc. | 0.4% | +135.4% |
| MERC | Mercer International Inc | 0.4% | -83.9% |
| REPL | Replimune Group Inc | 0.4% | +160.4% |
| VSTM | Verastem Inc | 0.3% | +42.1% |
| AIRJ | Montana Technologies Corporation | 0.2% | +43.4% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| May 4, 2026 | BUY | MERC | 0.6% → 0.4% |
| May 4, 2026 | BUY | IMTX | 6.4% → 6.6% |
| May 4, 2026 | SELL | GBX | 0.6% → 0.6% |
| May 4, 2026 | BUY | NVDA | 21.9% → 24.3% |
| May 4, 2026 | BUY | AIRJ | 0.0% → 0.2% |
Investment Style Analysis
Cowen Inc. is widely recognized for employing a Multi-Strategy strategy. As of Sep 21, 2026, the firm oversees approximately $0.8B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology and Semiconductors sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending May 4, Cowen Inc. made a significant move by increasing exposure to MERC. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
Cowen’s investment philosophy centers on a deep, research-driven understanding of specialized industry sectors to identify long-term value and growth opportunities. The firm utilizes its 'Ahead of the Curve' research framework to pinpoint secular shifts and emerging industries before they gain mainstream recognition. By combining rigorous fundamental analysis with sector-specific expertise in areas like healthcare, sustainability, and technology, Cowen aims to generate consistent alpha for its clients. Its alternative investment strategies are focused on risk-adjusted returns through active management and a collaborative approach that leverages the firm’s broad institutional platform.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Cowen Inc..
Similar Investment Style
Based on Multi-Strategy.
- Sandoz Family Office SA — Marc Duc · 3M -6.5%
- BB Gestão de Recursos - Distribuidora de Títulos e Valores Mobiliários S.A. — Denísio Liberato · 3M +6.1%
- Wolverine Trading, LLC — Robert Bellick · 3M +3.9%
- Amundi Asset Management US, Inc. — Marco Pirondini · 3M -0.4%
Frequently asked questions
How is the simulated portfolio for Cowen Inc. constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Cowen Inc.'s largest holding?
As of the latest filing, Cowen Inc.'s top position is PTC Therapeutics Inc (PTCT), representing 24.5% of the portfolio. This reflects a high-conviction bet by the institution.
What is Cowen Inc.'s historical performance and risk profile?
Our simulation indicates a total return of +20.0% with a win rate of 69%. Notably, the portfolio maintains a Sharpe Ratio of 3.24, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does Cowen Inc. primarily invest in?
Cowen Inc. has a strong preference for the Biotechnology sector, which makes up 58.0% of their disclosed assets. The portfolio also has exposure to Semiconductors, indicating a specific thematic focus.
Is Cowen Inc.'s portfolio concentrated or diversified?
Cowen Inc. runs a moderately concentrated portfolio with 20 disclosed positions. The top 3 holdings alone account for 61.2% of the total portfolio weight, suggesting a strategy that favors broader market exposure.
How has Cowen Inc. performed in 2026?
Our AI-simulated model portfolio for Cowen Inc. tracks a Year-to-Date (YTD) return of +1.6%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Jeffrey Solomon manage Cowen Inc. directly?
Yes, Jeffrey Solomon serves as the key portfolio manager for Cowen Inc., overseeing the investment strategy and final capital allocation decisions.